The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates to the treatment of individuals having systemic lupus erythematosus (SLE) using a bispecific antibody that targets CD20 and CD3 (e.g., mosunetuzumab). More specifically, the invention pertains to the treatment of individuals having SLE by subcutaneous administration of mosunetuzumab.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A method and system for generating a geographic atrophy (GA) lesion segmentation mask corresponding to GA lesions in a retina is disclosed herein. In some embodiments, a set of fundus autofluorescence (FAF) images of a retina having one or more geographic atrophy (GA) lesions and one or both of a set of infrared (IR) images of the retina or a set of optical coherence tomography (OCT) images of the retina may be used to generate the GA lesion segmentation mask including one or more GA lesion segments corresponding to the one or more GA lesions in the retina. In some instances, a neural network may be used to generate the GA lesion segmentation mask.
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
G06T 7/174 - SegmentationEdge detection involving the use of two or more images
G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume
The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G06F 16/28 - Databases characterised by their database models, e.g. relational or object models
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
5.
METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WITH MOSUNETUZUMAB
The present invention relates to the treatment of individuals having systemic lupus erythematosus (SLE) using a bispecific antibody that targets CD20 and CDS (e.g., mosunetuzumab). More specifically, the invention pertains to the treatment of individuals having SLE by subcutaneous administration of mosunetuzumab.
The present invention relates to methods for treating multiple sclerosis (MS) in a patient which in some cases involves subcutaneously administering an anti-CD20 antibody into the patient at a dose of about 920 mg. Compositions, formulations and articles of manufacture with instructions for such use are also included.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
7.
USE OF KOSMOTROPES TO ENHANCE YIELD OF AN AFFINITY CHROMATOGRAPHY PURIFICATION STEP
The present disclosure provides methods and kits for purifying an antigen binding protein comprising a VL domain using a Protein L chromatography material which includes kosmotrope salts in the buffer background.
The present invention relates to RG6035, a bispecific antibody against human CD20 and human transferrin receptor, for use in the treatment of multiple sclerosis.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 25/00 - Drugs for disorders of the nervous system
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A01K 67/0275 - Genetically modified vertebrates, e.g. transgenic
Disclosed are various embodiments for leveraging large language models (LLMs) and retrieval-augmented generation (RAG) for data standardization of clinical AI data. A query comprising a target dataset that needs to be standardized and a dataset dictionary can be obtained. Augmented data can be extracted from an external source. A prompt including the query and the augmented data can be generated and applied to a large language model configured to output a response to the query. The response can include the target dataset standardized according to a standard format.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
Methods of assessing disease severity in a subject with multiple sclerosis using item response theory and the Expanded Disability Status Scale are described Related methods of assessing the effect of a therapeutic, and selecting subjects for treatment or participation in a clinical trial are also described.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
12.
STIMULATORY ANTIGEN PARTICLES, METHODS OF PRODUCTION, AND METHODS OF USE THEREOF
The present disclosure provides cell stimulatory particles and methods of using same. Also provided are populations of cells produced using the cell stimulatory particles.
Systems and methods for training machine learning models are described. The methods may comprise, e.g., receiving a first plurality of images of tissue specimens stained with a histochemical stain; receiving a second plurality of images of the tissue specimens stained with an immunohistochemical stain; aligning corresponding pairs of images; segmenting the aligned corresponding pairs of images to generate first and second pluralities of segmented images; mapping segments in each segmented image of the first plurality to corresponding segments in an image of the second plurality; and generating labeled image data by labeling segments in the images of the first plurality as exhibiting a specified cellular feature (or biomarker) based on detection of a signal associated with the immunohistochemical stain. In some instances, the labeled image data can be used to train a machine learning model for a digital pathology application, e.g., the evaluation of colitis severity.
Association services, namely, promoting the interests of promoting the interests of former employees of a pharmaceutical and biotechnology company; business networking services, namely, providing career information, employment information, and a website featuring information in the fields of career development, employment opportunities, career resources, and business networking, and organizing business networking events for former employees of a pharmaceutical and biotechnology company.
Association services, namely, promoting the interests of former employees of a pharmaceutical and biotechnology company; business networking services, namely, providing career information, employment information, and a website featuring information in the fields of career development, employment opportunities, career resources, and business networking, and organizing business networking events for former employees of a pharmaceutical and biotechnology company.
Provided herein are methods of treating and/or managing non-Hodgkin lymphoma, which comprise administering to a patient 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (“Compound A, A-S, or A-R”), or an enantiomer or mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with glofitamab or mosunetuzumab.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
17.
SYSTEM AND METHOD FOR MULTIMODAL PREDICTION OF PATIENT OUTCOMES
A method of predicting overall survivability of a patient by a prediction system based on machine learning includes receiving, by the prediction system including a processor and a memory, a plurality of input modalities corresponding to the patient, the input modalities being of different types from one another, generating, by the prediction system, a plurality of intermediate features based on the plurality of input modalities, each input modality of the plurality of input modalities corresponding to one or more features of the plurality of intermediate features, and determining, by the prediction system, a survivability score corresponding to an overall survivability of the patient based on a fusion of the plurality of intermediate features.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
18.
GUIDED MACHINE LEARNING ENABLED GENERATION OF ANTIGEN RECEPTORS
A method may include identifying an antigen receptor repertoire having a plurality of different context. A target context, such as a target clonotype or lymphocyte maturity, is identified within the plurality of different context present in the antigen receptor repertoire. A protein design computation model is trained to generate to approximate a data distribution of protein sequences of antigen receptors exhibiting the target context. In some cases, the protein design computation model may be trained to approximate a data distribution of protein sequences of antigen receptors exhibiting multiple target contexts. In some cases, the protein design computation model may be applied to generate, based on an input protein sequence, an output protein sequence corresponding to at least a portion of an antigen receptor exhibiting the target context. Related systems and computer program products are also provided.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
Systems and methods of prediction of future tumor data. A tumor embedding at a neural ordinary differential equations (ODE) system is received. The tumor embedding is generated using a tumor encoder and observed tumor data that is observed over a selected period of time after a reference point in time. A graph embedding at the neural ODE is received. The graph embedding fuses drug information, disease information, and gene relationship information. The graph embedding is generated using a heterogenous graph encoder that fuses together at least two or more embeddings generated using bipartite graph convolution attention networks. A predicted tumor size at a future point in time is generated using the tumor embedding, the graph embedding, and the neural ODE system. A candidate tumor treatment is administered to a subject in response to the predicted tumor size being less than a selected threshold.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
22.
OCULAR CANNULA GUIDE, APPLICATOR, AND MARKING INSTRUMENT
An apparatus includes a pair of rigid legs extending parallel with each other along a plane. Each leg of the pair of legs has a sharp tip. The apparatus also includes head, including a top surface, a bottom surface, a pair of end surfaces, a pair of side surfaces, and a guide notch extending upwardly from the bottom surface. The guide notch is configured to cooperate with a surface of a sclera of a patient's eye to define a guide opening that is oriented transversely relative to the plane associated with the legs and that is sized to receive a cannula having a generally flat profile. The head further includes a pair of receptacles extending laterally inwardly from respective side surfaces of the pair of side surfaces. Each receptacle of the pair of receptacles is configured to engage a deployment instrument.
The present disclosure provides methods and compositions for treating inflammatory bowel disease (IBD), e.g., ulcerative colitis (UO) or Crohn's disease (CD), with a therapeutic dose of an anti- TNF-like ligand 1 A (TL1 A) agent (e.g., anti-TL1 A antibody) in pediatric patients.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
24.
ASSESSMENT OF SKIN TOXICITY IN AN IN VITRO TISSUE SAMPLES USING DEEP LEARNING
In one embodiment, a method includes receiving a querying image associated with a tissue sample after a treatment by a drug compound, identifying a target layer of the tissue sample based on a machine-learning model trained to identify layers of tissue samples, calculating a normalized thickness of the identified target layer, and determining a toxicity indication of the treatment by the drug compound based on the normalized thickness of the identified target layer.
A drug discovery ecosystem may receive one or more user inputs configuring an artificial intelligence (Al) agent for orchestrating a drug discovery workflow applying one or more drug discovery tools. The artificial intelligence (Al) agent may be created in accordance with the one or more user inputs. The artificial intelligence (Al) agent is served to one or more users as part a selection of artificial intelligence (Al) agents. One or more user inputs selecting the artificial intelligence (Al) agent may be received. The artificial intelligence (Al) agent may be executed to orchestrate the drug discovery workflow in response to the one or more user inputs selecting the artificial intelligence (Al) agent. Related systems, computer-implemented methods, and computer program products are provided.
G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
26.
MACHINE LEARNING ENABLED CHARACTERIZATION OF PROTEIN-PROTEIN INTERACTION SITES
A method may include receiving a pairing of a protein molecule amino acid residue sequence and a target molecule amino acid residue sequence. The protein molecule amino acid residue sequence may form a protein molecule and the target molecule amino acid residue may form a target molecule. A property computation model may be applied to determine a binding affinity between the protein molecule and the target molecule based on the protein molecule amino acid residue sequence the target molecule amino acid residue sequence. Feature attribution may be performed to identify, within the target molecule amino acid residue sequence and the protein molecule amino acid residue sequence, one or more positions in either amino acid residue sequence whose contribution to a binding affinity determination of the property computation model satisfies one or more thresholds. Interaction sites between the two molecules may be identified based on a result of the feature attribution.
A method may include receiving a candidate protein molecule. A property computation model is applied to determine, based on an amino acid residue sequence of the candidate protein molecule, one or more biophysical descriptors of the candidate protein molecule. The one or more biophysical descriptors define one or more surface properties approximating one or more developability traits of the candidate protein molecule. The candidate protein molecule is screened based on the one or more biophysical descriptors of the candidate protein molecule. Alternatively, the generating of one or more additional candidate protein molecules, for example, by modifying the amino acid residue sequence of the candidate protein molecule, is guided by the one or more biophysical descriptors of the candidate protein molecule. Related systems and computer program products are also provided.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Provided are combination therapies comprising inavolisib, a CDK4/6 inhibitor (e.g., palbociclib, ribociclib or abemaciclib), and letrozole; and methods of treating endocrine-sensitive PIK3CA-mutated, HR+ and HER2– advanced breast cancer in a patient comprising administering a therapeutically effective amount of inavolisib, a CDK4/6 inhibitor (e.g., palbociclib, ribociclib or abemaciclib), and letrozole.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A method may include receiving a candidate protein molecule. A property computation model is applied to determine, based on an amino acid residue sequence of the candidate protein molecule, one or more biophysical descriptors of the candidate protein molecule. The one or more biophysical descriptors define one or more surface properties approximating one or more developability traits of the candidate protein molecule. The candidate protein molecule is screened based on the one or more biophysical descriptors of the candidate protein molecule. Alternatively, the generating of one or more additional candidate protein molecules, for example, by modifying the amino acid residue sequence of the candidate protein molecule, is guided by the one or more biophysical descriptors of the candidate protein molecule. Related systems and computer program products are also provided.
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G06F 30/27 - Design optimisation, verification or simulation using machine learning, e.g. artificial intelligence, neural networks, support vector machines [SVM] or training a model
30.
DIAGNOSTIC AND THERAPEUTIC METHODS FOR TREATING LUNG CANCER
The invention provides diagnostic methods for identifying individuals having a lung cancer (e.g., NSCLC) suitable for treatment a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) after adjuvant therapy (e.g., after a platinum-based adjuvant therapy) and therapeutic methods for treating lung cancer (e.g., NSCLC) in an individual identified as one who may benefit from treatment with a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the individual following an adjuvant therapy (e.g., after a platinum-based adjuvant therapy). Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab), pharmaceutical compositions thereof, assays thereof, kits thereof, and articles of manufacture thereof) for use in identifying patients suitable for treatment and for treating lung cancer (e.g., NSCLC) in an identified individual.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Methods of treating patients having HER2-positive cancer are provided. Certain methods involve treatment of HER2 positive breast cancer using a programmed cell death protein 1 (PD-1) binding antagonist or a programmed death ligand 1 (PD-L1) binding antagonist in combination with trastuzumab and pertuzumab or with trastuzumab emtansine. The treatment regimen may be used in various clinical settings, for example, for treatment in the neoadjuvant or metastatic setting.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations containing ocrelizumab for the treatment of multiple sclerosis, pre-filled on-body injectors containing pharmaceutical preparations for the treatment of multiple sclerosis. Wearable on-body injectors for the subcutaneous administration of pharmaceutical preparations; medical drug delivery devices for administering pharmaceutical preparations.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations containing ocrelizumab for the treatment of multiple sclerosis, pre-filled on-body injectors containing pharmaceutical preparations for the treatment of multiple sclerosis. Wearable on-body injectors for the subcutaneous administration of pharmaceutical preparations; medical drug delivery devices for administering pharmaceutical preparations.
34.
AUTOMATED TUMOR IDENTIFICATION AND SEGMENTATION WITH MEDICAL IMAGES
Medical image(s) are input into a detection network to generate mask(s) identifying a set of regions within the medical image(s), where the detection network predicts that each region identified in the mask(s) includes a depiction of a tumor of one or more tumors within the subject. For each region, the region of the medical image(s) is processed using a tumor segmentation network to generate one or more tumor segmentation boundaries for the tumor present within the subject. For each tumor and by using a plurality of organ-specific segmentation networks, an organ is determined within which at least part of the tumor is located. An output is generated based on the one or more tumor segmentation boundaries and locations of the organs within which at least part of the one or more tumors are located.
The present disclosure provides methods and compositions for treating diabetic macular edema (DME) with an anti-tyrosine kinase with immunoglobulin-like loop epidermal growth factor homology domain 2 (Tie2) antibody conjugate.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
37.
Biomolecule Fitness Inference for Variant Nomination Using Machine Learning with Directed Evolution
In one embodiment, a method includes obtaining sequencing time-series data from a first round of directed evolution, wherein the sequencing time-series data for the first round comprises a first biomolecule frequency of a first biomolecule, the first biomolecule frequency of the first biomolecule being a non-zero frequency, obtaining sequencing time-series data from a second round of directed evolution, wherein the sequencing time-series data for the second round comprises a second biomolecule frequency of the first biomolecule, and outputting an inferred fitness score for the first biomolecule using the first biomolecule frequency and the second biomolecule frequency.
The current disclosure provides a method suitable for detecting barcode sequences in a biological sample in situ. Advantageously, the method can be effectively used to detect barcode sequences in formalin-fixed paraffin-embedded (FFPE) tissue samples.
The invention provides an effectorless immunoglobulin Fc protein, fusions of the effectorless Fc protein to a Flt3 ligand, and methods of using the same.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
40.
METHODS OF TREATING HER2-POSITIVE METASTATIC BREAST CANCER
Methods of treating patients having HER2-positive, locally advanced or previously untreated metastatic breast cancer having received prior treatment with a taxane using an anti-HER2-maytansinoid conjugate (for example trastuzumab emtansine) are provided.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
41.
PHARMACEUTICAL COMPOSITIONS COMPRISING AKT PROTEIN KINASE INHIBITORS
The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The present disclosure provides TROP2xEGFR bispecific antibodies, TROP2xFGFR1 bispecific antibodies, TROP2xFZD bispecific antibodies and compositions comprising such bispecific antibodies. The bispecific antibodies and related compositions may be used for the treatment of cancer. The present disclosure also provides polynucleotides, vectors, host cells and methods for expressing TROP2xEGFR bispecific antibodies, TROP2xFGFR1 bispecific antibodies, TROP2xFZD bispecific antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
43.
Semi-Automated High-Throughput Mid-Scale Protein Expression Methods
The present disclosure relates to a higher-throughput, mid-scale, semi-automated protein expression and screening platform that can be used, for instance, for drug discovery research and otherwise for testing protein expression conditions, among other uses. The workflow described here also in some embodiments enables comprehensive expression and purification screening assessment of challenging or difficult-to-express recombinant proteins in a faster and efficient manner by delivering small but sufficient amounts of high-quality proteins.
A method may include determining, within a first positron emission tomography and computed tomography (PET-CT) scan depicting a plurality of regions of a body, a first region including a lesion. A first portion of the first PET-CT scan depicting the first region but not a second region of the plurality of regions may be extracted to generate a second PET-CT scan having one or more initial dimensions. The one or more initial dimensions of the second PET-CT scan may be adjusted to one or more target dimensions by at least adding, to the second PET-CT scan, one or more voxels, and determining a value of each of the one or more voxels added to the second PET-CT scan. A segmentation model may be trained based on a training dataset that includes the second PET-CT scan adjusted to the one or more target dimensions.
Provided herein are fusion proteins that involve an antibody that binds to a target fused to a protease that cleaves a substrate, and the target is in the proximity of the substrate. The target and the substrate in some cases are the same molecule. Methods of making and using such fusion proteins are also provided.
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
46.
SEQUENCE-BASED MACHINE LEARNING ENABLED PROTEIN MOLECULE DESIGN WITH PROTEIN STRUCTURE REPRESENTATIONS
A method may include identifying an input molecule. A structural representation indicative of a conformation of the input molecule may be generated. In some cases, the structural representation may be a canonical conformation signature or a multimodal representation encoding the three-dimensional structural features of the input molecule. An output molecule may be generated by applying a molecule design computation model to modify the amino acid residue sequence of the input molecule. The modifying of the ammino acid residue sequence may be guided by the structural representations of the input molecule in order to preserve the conformation of the input molecule. In some cases, one or more properties of the output molecule may be determined based on the structural representation of the output molecule. Related systems and computer program products are also provided.
Provided herein are methods of treating cancers, inflammatory diseases, and autoimmune diseases and methods of modulating related phenotypes and expression levels by targeting interactions among E3 ligases, E3-like proteins, and their interacting partners. Methods of identifying modulators of such interactions are also provided. Also provided herein are cell therapies comprising alterations in at least two members of a co-functional gene module.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
49.
METHOD AND MEDICAMENT FOR TREATING CANCER UNRESPONSIVE TO PD-1/PD-L1 SIGNALING INHIBITOR
The present invention relates to medicaments, treatment methods, kits, and uses for treating cancer in individuals, characterized in that a VEGF signaling inhibitor and a PD-1/PD-L1 signaling inhibitor are administered in combination, as well as VEGF signaling inhibitors, PD-1/PD-L1 signaling inhibitors, and combinations thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Provided here are IRE1 degrader compounds comprising a protein target moiety covalently attached by a linker to an E3 ubiquitin ligase-binding moiety. Also provided are intermediate compositions for the preparation of IRE 1 degrader compounds and methods of treating diseases and disorders such as cancer with the IRE1 degrader compounds.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The present invention concerns methods for treating multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
54.
PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME
Pharmaceuticas composition comprising novel salts of Compound I, and methods of making and using the same, and related dosage forms thereof, are disclosed.
A61J 3/10 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
A61K 9/00 - Medicinal preparations characterised by special physical form
The present disclosure relates to methods for quantifying both lipid and nucleic acid cargo components of LNP formulations simultaneously, i.e., in a single chromatography separation process. In some embodiments, the methods comprise ion-pair reversed-phase high performance liquid chromatography (IPRP-HPLC) separation coupled with ultraviolet (UV) and charged aerosol detection (CAD). In some cases, the methods allow for quantification of the content of several different lipid and nucleic acid species in a single LNP formulation simultaneously, thus allowing for efficient characterization of LNP formulations, for example, for process control of pharmaceutical or test formulations.
The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of an anti-CD20/anti-CD3 bispecific antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Disclosed herein are compositions and methods for the treatment of systemic lupus erythematosus using anti-CD20/anti-CD3 bispecific antibodies, such as mosunetuzumab.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
58.
AUTOMATED FEATURE EXTRACTION FOR DIABETIC RETINOPATHY (DR) LESIONS AND/OR FEATURES USING DEEP LEARNING
A method and system for identifying and localizing lesions and/or features associated with diabetic retinopathy. CF imaging data may be received for a retina of a subject. An image input may be formed for a deep learning model using the CF imaging data. The deep learning model may be used to generate DR lesion detection output based on the image input. The DR lesion detection output may include an output based on segmentation, localization, quantification, and/or some other extraction of information related to the DR lesions and/or features.
A method and system for generating synthetic predicted OCT imaging data are provided. Input data including characteristic data and baseline imaging data associated with a subject at a baseline timepoint may be received. Input data associated with the subject for a set of future timepoints may be received. First and second machine learning models may be used to generate predicted OCT imaging data associated with the retina of the subject for the set of future timepoints, based on the input data.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
e.g.e.g., by mass spectrometry. In certain embodiments, methods of the present disclosure include the use of biotinylation and magnetic microparticles coupled to streptavidin to label and isolate cell surface proteins in small cell populations.
A training dataset is generated to include a plurality of training multicellular gene profiles. Each training multicellular gene profile being associated with a sample including a plurality of cells and including, for each cell, an expression level of each gene of a plurality of genes. A multicellular gene interaction computation model is trained by applying the multicellular gene interaction computation model to generate, for each gene in a training multicellular gene profile, a contextual gene embedding that captures a co-regulatory relationship between the gene and one or more other genes in the training multicellular gene profile. The trained multicellular gene interaction computation model is applied in one or more applications including, for example, receptor-ligand analysis, multicellular gene network inference, disease¬ specific gene identification, cell population-level perturbation effect prediction, recovery of spatial colocalization patterns, and/or the like.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
An exchange needle device having an elongate needle structure having an elongate tube extending distally from a proximal hub and an outer cannula extending distally from the proximal hub. The outer cannula surrounds at least a proximal end region of the elongate tube forming an annular space between the outer surface of the elongate tube and the inner surface of the outer cannula. The distal end of the outer cannula is located a distance proximal to the distal opening of the elongate tube. A lubricious coating is on the outer surface of the outer cannula and the outer surface of the elongate tube extending distal to the distal end of the outer cannula, the lubricious coating covering at least a portion of the working length of the elongate needle structure. Related devices, systems, and methods of use are provided.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
64.
ENHANCED SEPTUM RETENTION FOR IMPLANTED OCULAR DELIVERY SYSTEMS
An ophthalmic drug delivery device including a body defining a refillable reservoir; an extrascleral flange projecting from a proximal end of the body and defining a bore extending from an upper surface of the flange into the reservoir; a septum including an upper surface connected to a lower surface by a curved outer surface. The curved outer surface of the septum forms a first bond with the bore. A perimeter region of the upper surface of the septum lies flush with a plane of the upper surface of the flange and a central region of the upper surface lies below the perimeter region. An elastomeric encasement extends over at least the upper surface of the flange and the upper surface of the septum and prevents displacement of the septum relative to the bore upon penetration by a needle. Related devices, systems, and methods are provided.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio by partially or completely inactivating GDP-keto-6-deoxymannose-3,5-epimerase, 4-reductae (GDP-L-fucose synthase, EC 1.1.1.271) and additionally by adjusting the presence or absence of fucose source during culturing.
A method may include determining a protein sequence comprising a plurality of amino acid residues. An embedding computation model may be applied to generate an embedding of the protein sequence. The embedding computation model may have been trained, through contrastive learning, to generate similar embeddings for protein sequences exhibiting a threshold similarity in one or more specific regions and dissimilar embeddings for protein sequences failing to exhibit the threshold similarity in the one or more specific regions. The embedding generated by the embedding computation model may prioritize similarities in the one or more specific regions (e.g., CDR3) over similarities in other regions (e.g., framework region). One or more related groups of protein sequences may be identified based on the embedding of the protein sequence. A visual representation may be generated based on the one or more groups of related protein sequences. Related systems and computer program products are also provided.
This disclosure relates to eukaryotic cell culture media useful in the production of recombinant proteins from cultured cell lines. The eukaryotic cell culture media comprise integrated stress response inhibitor (ISRIB), and/or hypotaurine and/or increased level of iron, and/or suramin. The disclosure also provides methods using said eukaryotic cell culture media, e.g. for culturing mammalian cells with enhanced product titer, and/or growth, and/or viability and/or for producing a recombinant protein of comparable or better product quality by culturing a eukaryotic cell line that comprises a polynucleotide encoding the recombinant protein in said media under conditions suitable for production of the polypeptide. Also provided are use of the eukaryotic cell culture media for the production of a recombinant protein from a cultured cell line comprising a polynucleotide encoding the recombinant protein.
Aspects of the technology relate to methods and compositions for multiplexed assessment of perturbations with single cell molecular resolution using a regulatable Cas enzyme with intrinsic RNase activity.
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/537 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Provided herein are cell lines (e.g., HEK293 cell lines) that comprise a loss-of-function mutation in each of the human Bax and Bak genes, as well as cell cultures comprising the cell lines. The cell lines and/or cell cultures may find use, e.g., in methods for producing a recombinant polypeptide (such as an antibody or antigen-binding fragment thereof) or a viral vector.
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
The present disclosure provides methods of treating a steatotic liver disease associated with metabolic dysfunction, such as metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated fatty livers disease (MAFLD), or metabolic dysfunction-associated steatotic liver disease (MASLD). The treatment comprises administration of a dual GLP-1 receptor and GIP receptor agonist.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 9/00 - Medicinal preparations characterised by special physical form
The present disclosure provides methods of treating a steatotic liver disease associated with metabolic dysfunction, such as metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated fatty livers disease (MAFLD), or metabolic dysfunction-associated steatotic liver disease (MASLD). The treatment comprises administration of a dual GLP-1 receptor and GIP receptor agonist.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
74.
MACROPHAGE SIGNATURES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell-like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
75.
METHODS OF TREATING MULTIPLE SCLEROSIS WITH CD19-CD20 DUAL CAR-T CELLS
The present disclosure provides methods of treating multiple sclerosis (e.g. progressive MS or relapsing remitting MS) by administering a chimeric antigen receptor T cell (CAR-T cell) comprising an anti-CD20 chimeric antigen receptor and an anti-CD19 chimeric antigen receptor. The present disclosure also provides a dose infusion bag comprising a composition comprising CAR-T cells comprising an anti-CD20 chimeric antigen receptor and an anti-CD19 chimeric antigen receptor.
A plurality of molecule designs may be generated computationally. One or more property computation models may be applied to determine multiple properties of each molecule design. Each property computation model may be trained to approximate a probability distribution of the possible values of a corresponding property. A cumulative distribution function indicator corresponding to an expected multivariate rank may be determined for each molecule design based on the output of the property computation models. The multivariate rank of a molecule design may quantify the probability that none of its properties can be improved without degrading at least one other property. One or more molecule designs may be selected as candidates for wet lab assessment based on the cumulative distribution function indicator of each molecule design. The molecule designs that are selected for wet lab assessment may exhibit incrementally better properties than those from previous design iterations.
Provided herein are diagnostic and therapeutic methods for the treatment of cancer using polygenic risk scores (PRSs) for liver damage. In particular, the invention provides methods for patient selection and methods of treatment.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/52 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase involving transaminase
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
79.
METHODS OF TREATING LUPUS WITH CD19-CD20 DUAL CAR-T CELLS
e.g.e.g. highly active, severe, treatment-refractory systemic lupus erythematosus) by administering a chimeric antigen receptor T cell (CAR-T cell) comprising an anti-CD20 chimeric antigen receptor and an anti-CD19 chimeric antigen receptor. The present disclosure also provides a dose infusion bag comprising a composition comprising CAR-T cells comprising an anti-CD20 chimeric antigen receptor and an anti-CD19 chimeric antigen receptor.
Provided herein are methods of treating and/or managing non-Hodgkin lymphoma, which comprise administering to a patient 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3- morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione ("Compound A, A-S, or A- R"), or an enantiomer or mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with glofitamab or mosunetuzumab.
An image depicting a tissue sample is received. One or more tissue compartments present in the image of the tissue sample are identified including by generating a compartment map identifying pixels in the image depicting the tissue compartments. One or more cells present in the image of the tissue sample are identified including by generating a cell map identifying pixels in the image depicting the cells. A density-based pathology signature for the image of the tissue sample is determined based on the compartment map and the cell map. The density-based pathology signature includes a density of each cell type present in the one or more tissue compartments. A response computation model is applied to determine, based on the density-based pathology signature, a predictive output indicative of a likelihood of a patient associated with the tissue sample responding to an anticancer therapy such as immunotherapy.
41 - Education, entertainment, sporting and cultural services
Goods & Services
Ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instruments, namely, surgical instruments for use in delivery and administration of fluid, biologics and pharmaceuticals during ophthalmic surgery; apparatus and instruments for treating the eye, namely, cannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; apparatus and instruments for treating the eye, namely, cannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof, namely, devices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologic, cell therapy and gene therapy products; cannulas and needles for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; adhesive pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; magnetic pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space Training services in the field of ophthalmic surgical procedures; training services in the field of ophthalmic surgical equipment and the use and operation thereof; educational services, namely, conducting in-person classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, conducting online classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing in-person instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing online instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive in-person training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive online training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment
41 - Education, entertainment, sporting and cultural services
Goods & Services
Ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instruments, namely, surgical instruments for use in delivery and administration of fluid, biologics and pharmaceuticals during ophthalmic surgery; apparatus and instruments for treating the eye, namely, cannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; apparatus and instruments for treating the eye, namely, cannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof, namely, devices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologic, cell therapy and gene therapy products; cannulas and needles for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; adhesive pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; magnetic pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space Training services in the field of ophthalmic surgical procedures; training services in the field of ophthalmic surgical equipment and the use and operation thereof; educational services, namely, conducting in-person classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, conducting online classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing in-person instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing online instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive in-person training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive online training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment
84.
ANTI-INTERLEUKIN-23 RECEPTOR VHH ANTIBODIES AND USES THEREOF
Interleukin-23 receptor (IL23R) VHH antibodies are disclosed, as well as methods of making and using the same, e.g., for treatment of IL23-mediated diseases and disorders, including, e.g., gastrointestinal-related (Gl-related) diseases (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC) or Crohn's disease (CD)), a colon cancer, a small intestine cancer, a gastric cancer, an irritable bowel syndrome, a gastrointestinal ulcer, a gut-associated infection (e.g., a Salmonella infection or a Clostridium difficile infection), celiac disease, or pathogenic inflammation).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
85.
COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
The present invention relates to methods for treating multiple sclerosis (MS) in a patient which in some cases involves subcutaneously administering an anti-CD20 antibody into the patient at a dose of about 920 mg. Compositions, formulations and articles of manufacture with instructions for such use are also included.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
86.
MANAGING CLINICAL TRIAL PROGRESSION USING MACHINE LEARNING-BASED DATA
Systems and methods for managing progression of a clinical trial. Input data for a machine learning model is formed, based on longitudinal data for clinical trial cohort. The input data corresponds to input features and the cohort includes a plurality of subjects. A clinical outcome output is generated for each subject, using the machine learning model and a portion of the input data corresponding to each subject. Feature importance values are generated, based on the machine learning model generating the clinical outcome output for each subject. The feature importance values include, for each subject, a set of feature importance values for a set of input features. A ratio of interest is computed using the plurality of feature importance values. An output is generated using the ratio of interest in which the output indicates whether the cohort should proceed to a next phase of the clinical trial.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Apparatus and methods for filtering syringe fluid contents through a syringe-embedded filter. The filter may be sealed within a housing lodged distal to unfiltered fluid contents, proximal a syringe distal outlet, with a housing exterior sealed fluid-tight against a syringe inner wall. Before filtering, the housing may block access of unfiltered fluid to the filter. The unfiltered fluid may be sealed between a syringe plunger, the inner wall and the housing. Distally directed urging of the unfiltered fluid may unblock the housing to a flow of unfiltered fluid to the filter. Fluid-tight sealing within the housing may limit fluid passage to the distal outlet to a path through the filter. The unfiltered fluid may be urged through the unblocked housing and the filter. Filtered fluid, relatively free of particulate matter sized greater than a filter average pore size, may flow to the distal outlet for delivery to a target site.
Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
The present invention relates to methods of treating B-cell lymphomas, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20/anti-CD3 bispecific antibody (e.g., glofitamab) and in combination with one or more anti-CD20 antibodies (e.g., obinutuzumab and/or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and/or etoposide.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A method for predicting responsiveness to a HER2-directed therapy by assessing HER2 heterogeneity in a tumor includes contacting a sample of the tumor with a biomarker-specific reagent that specifically binds to HER2 protein and detecting HER2 protein in the sample, contacting the sample of the tumor with a first nucleic acid probe that specifically binds HER2 genomic DNA and detecting HER2 gene amplification status in the sample, contacting the sample of the tumor with a second nucleic acid probe that specifically binds HER2 RNA and detecting HER2 RNA status in the sample scoring the HER2 protein (IHC), HER2 gene (DISH), and HER2 RNA (RNA-ISH), predicting that the tumor is responsive to the HER2-directed therapy if the tumor reveals a first foci having a first score and a second score, in which the first score and the second score are not the same.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
The present application provides methods of treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies and anti-B cell maturation factor (BCMA)/anti-CD3 bispecific antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
95.
COMBINATION TREATMENT OF AN ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND CHEMOTHERAPY
The present invention relates to methods of treating B-cell lymphomas, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20/anti-CD3 bispecific antibody (e.g., glofitamab) and in combination with one or more anti-CD20 antibodies (e.g., obinutuzumab and/or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and/or etoposide.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
96.
SYNTHESIS OF TERT-BUTYL(LR,2S,5S)-2-((S)-L-HYDROXYETHYL)-2-METHYL-3,8- DIAZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE AND INTERMEDIATES THERETO
Provided herein are improved methods to produce diazabicyclo compounds, which may be useful in the production of small molecule KRAS inhibitors. Also provided are new intermediates compounds that may be useful in said processes.
C07D 207/20 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
The present application relates to aqueous pharmaceutical formulations for subcutaneous administration comprising an anti-CD20 antibody at a concentration of 100 mg/ml to 120 mg/ml. The formulation further comprises sodium acetate, sucrose, methionine, polysorbate, hyaluronidase, and polyvinylpyrrolidone (PVP) K12. Articles of manufacture that comprise such formulations and methods of treatment that involve the use of such formulations are also included.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Described herein are methods and systems for determining gene alteration states from pathology images. Also described are methods of selecting a treatment for a medical disease, and treating a patient in need thereof, by determining gene alteration states from pathology images. The disclosed methods and systems may also be used to investigate and identify biomarkers corresponding to gene alteration statues of interest.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
99.
MACHINE LEARNING ENABLED ANALYSIS OF COMPUTED TOMOGRAPHY AND POSITRON EMISSION TOMOGRAPHY SCANS FOR CELL-OF-ORIGIN PREDICTION
A method may include receiving a positron emission tomography (PET) scan depicting a plurality of cancerous cells. One or more lesions depicted in the positron emission tomography (PET) scan may be identified. A cell-of-origin classification model may be applied to determine a cell-of-origin of each lesion depicted in the positron emission tomography (PET) scan. A molecular subtype profile for the plurality of cancerous cells depicted in the positron emission tomography (PET) may be determined based at least on the cell-of-origin of the individual lesions depicted in the positron emission tomography (PET) scan. The molecular subtype profile may include an overall cell-of-origin of the plurality of cancerous cells and/or a proportion of lesions having each possible cell-of-origin. Related systems and computer program products are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
